Back to Search Start Over

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 , OPRM1 , and COMT Genotypes and Select Opioid Therapy

Authors :
Caroline Flora Samer
Larisa H. Cavallari
Andrew A. Monte
Andrew A. Somogyi
Rachel Huddart
Evan D. Kharasch
Kelly E. Caudle
Gualberto Ruaño
J. Steven Leeder
Andrea Gaedigk
Sara L. Van Driest
Cynthia A. Prows
Kristine R. Crews
Teri E. Klein
Todd C. Skaar
Henry M. Dunnenberger
Cyrine E. Haidar
Daniel J. Müller
John T. Callaghan
Mohamed Nagy
Katrin Sangkuhl
Source :
Clin Pharmacol Ther, Clinical Pharmacology and Therapeutics (2021)
Publication Year :
2021
Publisher :
Wiley, 2021.

Abstract

Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone, oxycodone, and methadone). Polymorphisms in CYP2D6 have been studied for an association with the clinical effect and safety of these drugs. Other genes that have been studied for their association with opioid clinical effect or adverse events include OPRM1 (mu receptor) and COMT (catechol-O-methyltransferase). This guideline updates and expands the 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and codeine therapy and includes a summation of the evidence describing the impact of CYP2D6, OPRM1, and COMT on opioid analgesia and adverse events. We provide therapeutic recommendations for the use of CYP2D6 genotype results for prescribing codeine and tramadol and describe the limited and/or weak data for CYP2D6 and hydrocodone, oxycodone, and methadone, and for OPRM1 and COMT for clinical use.

Details

ISSN :
15326535 and 00099236
Volume :
110
Database :
OpenAIRE
Journal :
Clinical Pharmacology & Therapeutics
Accession number :
edsair.doi.dedup.....5ec025355c1679cbc2986e0e2e94990d
Full Text :
https://doi.org/10.1002/cpt.2149